American Diabetes Association Scientific Sessions
CGM lowers health care costs, improves adherence vs. SMBG
ORLANDO, Fla. — Among patients with type 1 and type 2 diabetes prescribed multiple daily injection therapy, the use of continuous glucose monitoring was associated with lower health care costs and improved adherence vs. self-monitoring blood glucose, according to findings presented here.
In #MeToo era, ‘blind spots’ persist in endocrinology, clinical sciences
ORLANDO, Fla. — As the #MeToo era brings a heightened awareness to endocrinology, academic medicine and the clinical sciences, key gender disparities and reports of harassment continue to persist, challenging everyone to work harder to tackle the issue, according to two speakers here.
Switch from analogue to human insulin reduces part D coverage gap risk for Medicare beneficiaries
ORLANDO, Fla. — Medicare beneficiaries with type 2 diabetes switched from analogue to human insulin were less likely to reach the spending limit for their Part D drug plan — commonly known as the “donut hole” — with no changes in hospitalization rates for hypoglycemia or hyperglycemia and only a slightly increased mean HbA1c, according to a speaker here.
Role for dairy in diabetes risk reduction debated
ORLANDO, Fla. — A review of prospective, observational studies suggests there is a 4% to 10% decrease in the risk for developing diabetes with higher dairy consumption, but more studies are needed to solidify the association, according to a speaker here.
In type 2 diabetes, clinical inertia persists across health care organizations
ORLANDO, Fla. — For patients with type 2 diabetes, a large database analysis suggests a lack of clinical action in the 6 months after an HbA1c diagnosis of at least 8%, contradicting guidelines issued by the American Diabetes Association, according to a speaker here.
Experts separate dietary myth from science
ORLANDO, Fla. — Eating patterns, such as the Mediterranean diet and the Dietary Approaches to Stop Hypertension, or DASH, diet, are the most highly recommended for patients with diabetes, but a healthy diet should focus on individual needs and goals, according to a panel discussion here.
Semaglutide outperforms dulaglutide across all strata of HbA1c
ORLANDO, Fla. — Semaglutide yielded greater HbA1c and weight reductions compared with dulaglutide across all levels of HbA1c, according to findings from a post-hoc analysis of the SUSTAIN 7 study.
Long-term testosterone therapy may prompt type 2 diabetes remission in men
ORLANDO, Fla. — Among men with hypogonadism included in a urology registry, long-term treatment with testosterone may lead to remission of type 2 diabetes, according to a speaker.
Evolocumab reduces LDL, non-HDL in high-risk patients with type 2 diabetes
ORLANDO, Fla. — Treatment with the PCSK9 inhibitor evolocumab on top of maximally tolerated statin therapy resulted in significant reductions in LDL cholesterol and non-HDL cholesterol among patients with type 2 diabetes and hypercholesterolemia or mixed dyslipidemia enrolled in the BANTING study.
VADT: After 15 years, a debate over glucose-lowering ‘legacy effect’
ORLANDO, Fla. — Long-term follow-up of the Veterans Affairs Diabetes Trial suggests that adults with advanced type 2 diabetes assigned to intensive glucose-lowering therapy for an average of 5 years do not experience a “legacy effect” with respect to reduced microvascular or macrovascular complications 10 years after the intervention ends, according to an analysis presented here.